Human papillomavirus type 16 E6 inhibits p21WAF1 transcription independently of p53 by inactivating p150Sal2

Virology

Volumn 417, Issue 2, 2011, Pages 443-448

  Parroche, Peggy ^a,b   Touka, Majid ^a   Mansour, Mariam ^a   Bouvard, Véronique ^a   Thépot, Amélie ^a   Accardi, Rosita ^a   Carreira, Christine ^a   Roblot, Guillaume G ^b   Sylla, Bakary S ^a   Hasan, Uzma ^a,b   Tommasino, Massimo ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b University Lyon i   (France)

Author keywords

HPV16 E6; P150Sal2; P21WAF1 down regulation; P53

Indexed keywords

CELL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN E6; PROTEIN P150 SAL2; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPLICATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; REGULATORY MECHANISM; VIRUS MUTANT;

HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 80051918693     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.05.016     Document Type: Article

References (24)

1. Accardi R., Dong W., Smet A., Cui R., Hautefeuille A., Gabet A.S., Sylla B.S., Gissmann L., Hainaut P., Tommasino M. Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep. 2006, 7(3):334-340.
2. Caldeira S., Zehbe I., Accardi R., Malanchi I., Dong W., Giarre M., de Villiers E.M., Filotico R., Boukamp P., Tommasino M. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J. Virol. 2003, 77(3):2195-2206.
3. Chen J., Jackson P.K., Kirschner M.W., Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 1995, 374(6520):386-388.
4. Clifford G.M., Smith J.S., Plummer M., Munoz N., Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 2003, 88(1):63-73.
5. Ekholm S.V., Reed S.I. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr. Opin. Cell Biol. 2000, 12(6):676-684.
6. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75(4):817-825.
7. Funk J.O., Waga S., Harry J.B., Espling E., Stillman B., Galloway D.A. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 1997, 11(16):2090-2100.
8. Hasan U.A., Caux C., Perrot I., Doffin A.C., Menetrier-Caux C., Trinchieri G., Tommasino M., Vlach J. Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc. Natl Acad. Sci. U. S. A. 2007, 104(19):8047-8052.
9. Jones D.L., Alani R.M., Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev. 1997, 11(16):2101-2111.
10. Kaldis P., Aleem E. Cell cycle sibling rivalry: Cdc2 vs. Cdk2. Cell Cycle 2005, 4(11):1491-1494.
11. Kao W.H., Beaudenon S.L., Talis A.L., Huibregtse J.M., Howley P.M. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. J. Virol. 2000, 74(14):6408-6417.
12. Li D., Dower K., Ma Y., Tian Y., Benjamin T.L. A tumor host range selection procedure identifies p150(sal2) as a target of polyoma virus large T antigen. Proc. Natl Acad. Sci. U. S. A. 2001, 98(25):14619-14624.
13. Li D., Tian Y., Ma Y., Benjamin T. p150(Sal2) is a p53-independent regulator of p21(WAF1/CIP). Mol. Cell. Biol. 2004, 24(9):3885-3893.
14. Liu Y., Chen J.J., Gao Q., Dalal S., Hong Y., Mansur C.P., Band V., Androphy E.J. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J. Virol. 1999, 73(9):7297-7307.
15. Malanchi I., Accardi R., Diehl F., Smet A., Androphy E., Hoheisel J., Tommasino M. Human papillomavirus type 16 E6 promotes retinoblastoma protein phosphorylation and cell cycle progression. J. Virol. 2004, 78(24):13769-13778.
16. Malanchi I., Caldeira S., Krutzfeldt M., Giarre M., Alunni-Fabbroni M., Tommasino M. Identification of a novel activity of human papillomavirus type 16 E6 protein in deregulating the G1/S transition. Oncogene 2002, 21(37):5665-5672.
17. Mansour M., Touka M., Hasan U., Bellopede A., Smet A., Accardi R., Gabet A.S., Sylla B.S., Tommasino M. E7 properties of mucosal human papillomavirus types 26, 53 and 66 correlate with their intermediate risk for cervical cancer development. Virology 2007, 367(1):1-9.
18. Mantovani F., Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001, 20(54):7874-7887.
19. Morgenstern J.P., Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 1990, 18(12):3587-3596.
20. Munger K., Baldwin A., Edwards K.M., Hayakawa H., Nguyen C.L., Owens M., Grace M., Huh K. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 2004, 78(21):11451-11460.
21. Nielsen T.O., Hsu F.D., O'Connell J.X., Gilks C.B., Sorensen P.H., Linn S., West R.B., Liu C.L., Botstein D., Brown P.O., van de Rijn M. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am. J. Pathol. 2003, 163(4):1449-1456.
22. Sherr C.J., McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002, 2(2):103-112.
23. Zannetti C., Bonnay F., Takeshita F., Parroche P., Menetrier-Caux C., Tommasino M., Hasan U.A. C/EBP{delta} and STAT-1 are required for TLR8 transcriptional activity. J. Biol. Chem. 2010, 285(45):34773-34780.
24. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 2000, 92(9):690-698.